Actively Recruiting

Phase 2
Age: 80Years +
FEMALE
Healthy Volunteers
NCT07123649

Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study

Led by Dana-Farber Cancer Institute · Updated on 2026-04-22

364

Participants Needed

1

Research Sites

208 weeks

Total Duration

On this page

Sponsors

D

Dana-Farber Cancer Institute

Lead Sponsor

N

National Institute on Aging (NIA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.

CONDITIONS

Official Title

Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study

Who Can Participate

Age: 80Years +
FEMALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Women aged 60 80 years at the time of registration
  • History of stage 0-III breast cancer including ductal carcinoma in situ or invasive breast cancer of any subtype
  • No history of recurrent breast cancer considered metastatic or locoregional recurrence by clinician judgement
  • At least one intact breast
  • Mammogram screening or surveillance within the last 24 months
  • At least 12 months since most recent breast surgery to the affected breast
  • No active cancer treatment except hormonal therapy or CDK 4/6 inhibitor therapy
  • Ability and willingness to take surveys
  • Receiving some oncology follow-up care at a participating site
  • Most recent mammogram report did not recommend additional diagnostic work-up or close interval follow-up imaging, or any required diagnostic testing was resolved to benign findings
Not Eligible

You will not qualify if you...

  • Inability to provide informed consent
  • Assigned male sex at birth
  • Breast or recent imaging findings requiring diagnostic testing at baseline
  • Prior discontinuation of mammography by medical record or patient report
  • Prior atypical ductal hyperplasia or non-pleomorphic lobular carcinoma in situ only
  • Psychiatric illness limiting study compliance
  • Metastatic breast cancer
  • Receiving hospice care
  • Clinician unwilling to participate
  • Pregnant women, young patients, or those in prison

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02115

Actively Recruiting

Loading map...

Research Team

R

Rachel Freedman, MD, MPH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

HEALTH_SERVICES_RESEARCH

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here